Role of the gastric refluxate in gastroesophageal reflux disease: Acid, weak acid and bile

American Journal of the Medical Sciences

Volumn 338, Issue 2, 2009, Pages 89-95

  Richter, Joel E ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Acid reflux; Bile reflux; Impedance pH testing; Non acid reflux

Indexed keywords

BILE ACID; CISAPRIDE; PEPSIN A; PROKINETIC AGENT; PROTON PUMP INHIBITOR; TRYPSIN;

ACIDITY; AIRWAY OBSTRUCTION; BARRETT ESOPHAGUS; BILE REFLUX; DISEASE SEVERITY; DRUG MEGADOSE; DUODENOGASTRIC REFLUX; ESOPHAGITIS; ESOPHAGUS INJURY; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MECHANICAL STIMULATION; NONHUMAN; ODYNOPHAGIA; PATHOPHYSIOLOGY; PHARMACOLOGICAL BLOCKING; REFLUX ESOPHAGITIS; REVIEW; SINGLE DRUG DOSE; STOMACH ACID; STOMACH CONTENT; STOMACH MUCOSA LESION; STOMACH PH;

EID: 69349102776     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181ad584a     Document Type: Article

References (65)

1. Vakil N, van Zanten SV, Kharilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-1920
2. Fass R, Tougas G. Functional heartburn: the stimulus, the pain and the brain. Gut 2002;51:855-892
3. Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 mg once daily, omeprazole 20 mg once daily or ranitidine 150 mg twice daily, evaluated as initial therapy for the relief of symptoms of GERD in general practice. Scand J Gastroenterol 1997;32:965-973
4. van Pinxteren B, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2RAs and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cohcrane Database Syst Rev 2004;3:CD002095.
5. Tuttle SG, Rufin F, Battaneloo A. The physiology of heartburn. Ann Intern Med 1961;55:292-300.
6. Hirano I, Richter JE; Practice Parameters Committee of the American College of Gastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007;102:668-685
7. Pandolfino JE, Richter JE, Ours T, et al. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol 2003;98:740-749
8. Bredenoord AJ, Weusten BL, Smout AJ. Symptom association analysis in ambulatory gastro-oesophageal reflux monitoring. Gut 2005;54:1810-1817
9. Vaezi MF, Singh S, Richter JE. Role of acid and duodenogastric reflux in esophageal mucosal injury: a review of animal and human studies. Gastroenterology 1995;108:1897-1907.
10. Lillemoe KD, Johnson LE, Harmon JW. Alkaline esophagitis: a comparison of the ability of the components of gastroduodenal contents to injure rabbit mucosa. Gastroenterology 1983;85:621-628
11. Stein HJ, Barlow AP, DeMeester TR, et al. Complication of gastroesophageal reflux disease. Ann Surg 1992;216:35-43.
12. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996;111:1192-1199
13. Iascone C, DeMeester TR, Little AG, et al. Barrett's esophagus: functional assessment, proposed pathogenesis and surgical therapy. Arch Surg 1983;118:543-549
14. DeMeester TR, Johnson LF, Guy JI, et al. Patterns of gastroesophageal reflux in health and disease. Ann Surg 1976;184:459-470
15. Stein HJ, Hoeft S, DeMeester TR. Functional foregut abnormalities in Barrett's esophagus. J Thorac Cardiovasc Surg 1993;105:107-111
16. Fass R, Hell RW, Garewal RS, et al. Correlation of oesophageal acid exposure with Barrett's oesophagus length. Gut 2001;48:310-313
17. Orlando RC, Bryson JC, Powell DW. Mechanism of H+ injury in rabbit esophageal epithelium. Am J Physiol 1984;246:G718-24.
18. Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999;159:649-655
19. Miner P, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:2616-2621
20. Smith JL, Opekun AR, Larkai E, et al. Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology 1989;96:683-689
21. Baldi F, Ferrarini F, Longanesi A, et al. Acid gastroesophageal reflux and symptom occurrences. Dig Dis Sci 1989;34:1890-1893
22. Weusten BL, Akkermans LM, VanBerge-Henegouwen GP, et al. Symptom perception in gastroesophageal reflux disease is dependent on spatiotemporal reflux characteristics. Gastroenterology 1995;108:1739-1744
23. Cicala M, Emerenziani S, Caviglia R, et al. Intra-oesophageal distribution and perception of acid reflux in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003;18:605-613
24. Holzer P. TRPV1: a new target for treatment of visceral pain in IBS? Gut 2008;57:882-884
25. Matthews PJ, Aziz Q, Facer P, et al. Increased capsaicin receptor TRPV1 nerve fibres in the inflamed human oesophagus. Eur J Gastroenterol Hepatol 2004;16:897-902.
26. Malenstein HV, Farre R, Sifrim D. Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease. Am J Gastroenterol 2008;103:1021-1028
27. Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology 2005;128:771-778
28. Calabrese C, Bortolotti M, Fabbri A, et al. Reversibility of GERD ultrastructural alteration and relief of symptoms after omeprazole treatment. Am J Gastroenterol 2005;100:537-542
29. Bredenoord AJ, Tutuian R, Smout AJ, et al. Technology review: esophageal impedance monitoring. Am J Gastroenterol 2007;102:187-194
30. Sifrim D, Castell D, Dent J, et al. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid and gas reflux. Gut 2004;53:1024-1031
31. Shay S, Tutuian R, Sifrim D, et al. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values for 60 healthy volunteers. Am J Gastroenterol 2004;99:1037-1043
32. Zerbib F, des Varannes SB, Roman S, et al. Normal values and day-to-day variability of 24 hour ambulatory oesophageal pH-impedance monitoring in a Belgian-French cohort of healthy subjects. Aliment Pharmacol Ther 2005;22:1011-1021
33. Adhami T, Goldblum JR, Richter JE, et al. The role of gastric and duodenal agents in laryngeal injury: an experimental canine model. Am J Gastroenterol 2004;99:2098-2106
34. Kennedy TP, Johnson KJ, Kunkel RG, et al. Acute acid aspiration lung injury in the rat: biphasic pathogenesis. Anesth Analg 1989;69:87-92.
35. Schwartz DJ, Wynne JW, Gibbs CP, et al. The pulmonary consequences of aspiration of gastric contents of pH values greater than 2.5. Am Rev Resp Dis 1980;121:119-126
36. Sifrim D, Dupowt G, Bondreau K, et al. Weakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH and impedance monitoring. Gut 2005;54:449-454
37. Bredenoord AJ, Weusten BL, Curvers WL, et al. Determinants of perception of heartburn and regurgitation. Gut 2006;55:313-318
38. Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006;101:1956-1963
39. Maine I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006;55:1398-1402
40. Taghavi SA, Ghasedi M, Saberi-Firoonz M, et al. Symptom association probability and symptom sensitivity index: preferable but still suboptimal predictors of response to high dose omeprazole. Gut 2005;54:1067-1071
41. Vela MF, Tutuian R, Katz PO, et al. Baclofen decreases acid and non-acid postprandial gastro-oesophageal reflux by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2007;26:61-68
42. Conchillo JM, Schwartz MP, Selimach M, et al. Role of intraoesophageal impedance monitoring in the evaluation of endoscopic gastroplication for GERD. Aliment Pharmacol Ther 2007;26:61-68
43. Maine I, Tutuian R, Agrawal A, et al. Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg 2006;93:1483-1487
44. Vaezi MF, LaCamera RG, Richter JE. Bilitec 2000 ambulatory duodenogastric reflux monitoring. Studies on its validation and limitations. Am J Physiol 1994;30:1050-1056
45. Sifrim D, Mittal R, Fass R, et al. Review article: acidity and volume of the refluxate in the genesis of gastro-oesophageal reflux disease symptoms. Aliment Pharmacol Ther 2007;25:1003-1015
46. Harmon JW, Johnson LF, Maydonovitch CL. Effects of acid and bile salts on the rabbit esophageal mucosa. Dig Dis Sci 1981;26:65-72.
47. Lillemoe KD, Johnson LF, Harmon JW. Role of the components of the gastroduodenal contents to injure rabbit mucosa. Surgery 1982;92:276-284
48. Batzri S, Harmon JW, Schweitzer EJ, et al. Bile acid accumulation in gastric mucosal cells. Proc Soc Exp Biol Med 1991;197:393-399
49. Orlando RC, Bozymski EM. Heartburn in pernicious anemia - a consequence of bile reflux. N Engl J Med 1973;289:522-523
50. Matikainen M, Laatikainen T, Kalima T, et al. Bile acid composition and oesophagitis after total gastrectomy. Am J Surg 1982;143:196-198
51. Vaezi MF, Richter JE. Synergism of acid and duodenogastroesophageal reflux in complicated Barrett's esophagus. Surgery 1995;117:699-704.
52. Koek GH, Sifrim D, Lerut T, et al. Multivariate analysis of the association of acid and duodeno-gastro-oesophageal reflux exposure with the presence of oesophagitis, the severity of oesophagitis and Barrett's esophagus. Gut 2006;57:1056-1064
53. Campos GM, DeMeester SR, Peters JH, et al. Predictive factors of Barrett's esophagus: multivariate analysis of 502 patients with GERD. Arch Surg 2001;136:1267-1273
54. Tselepis C, Morris CD, Wakelin D, et al. Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut 2003;52:174-180
55. 2 release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-ε dependent. Am J Physiol Gastrointest Liver Physiol 2002;283:G327-34.
56. Siddiqui A, Rodriguez-Stanley S, Suzbaidi S, et al. Esophageal visceral hypersensitivity to bile salts in patients with functional heartburn and in healthy control subjects. Dig Dis Sci 2005;50:81-85
57. Tack J. Review article: the role of bile and pepsin in the pathophysiology and treatment of GERD. Aliment Pharmacol Ther 2006;24(suppl):10-16
58. Koek GH, Tack J, Sifrim D, et al. The role of acid and duodenal gastroesophageal reflux in symptomatic GERD. Am J Gastroenterol 2001;96:2033-2040
59. Tack J, Koek G, Demedts I, et al. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux or both? Am J Gastroenterol 2004;99:981-988
60. Champion G, Richter JE, Vaezi MF, et al. Duodenogastroesophageal reflux: relationship to pH and importance in bile reflux. Gastroenterology 1994;10:747-754
61. Marshall RE, Anggiansah A, Manifold DK, et al. Effect of omeprazole 20 mg BID on duodenogastric and gastro-oesophageal bile reflux in Barrett's esophagus. Gut 1998;43:603-606
62. Stein HJ, Kauer WK, Feussner H, et al. Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and Nissen fundoplication. J Gastrointest Surg 1982;2:333-341
63. Vaezi MF, Sean R, Richter JE. Placebo-controlled trial of cisapride in post-gastrectomy patients with duodenogastroesophageal reflux. Dig Dis Sci 1996;41:754-763
64. β agonist baclofen in patients with symptoms and DGER refractory to proton pump inhibitors. Gut 2003;10:1397-1402
65. Ang D, Sifrim D, Tack J. Mechanisms of heartburn. Nat Clin Pract Gastroenterol Hepatol 2008;5:383-392